Please login to the form below

Not currently logged in
Email:
Password:

Roivant

This page shows the latest Roivant news and features for those working in and with pharma, biotech and healthcare.

Myovant has second phase 3 trial to back its uterine fibroids drug

Myovant has second phase 3 trial to back its uterine fibroids drug

The company, part of the Swiss Roivant group headed by Vivek Ramaswamy, says the LIBERTY 2 trial showed a 71.2% response rate for once-daily relugolix in women with uterine

Latest news

More from news
Approximately 6 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    110. Arena Pharmaceuticals/ Roivant Sciences. Licence agreement. For Nelotanserin a 5-HT2A receptor P2 in behavioural and neuropsychiatric disturbances.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics